Gilead stops last PhI­II of CD47 drug, cit­ing FDA hold, high­er risk of death in treat­ment arm

Gilead dis­con­tin­ued its re­main­ing Phase III study of ma­grolimab, an an­ti-CD47 an­ti­body that the com­pa­ny was test­ing for acute myeloid leukemia and its pre­cur­sor dis­ease, and it will not pur­sue fu­ture work on this ther­a­py in blood can­cers.

In an in­ter­im analy­sis, pa­tients who re­ceived ma­grolimab had an in­creased risk of death com­pared to those who re­ceived stan­dard care with Ab­b­Vie and Roche’s Ven­clex­ta and azac­i­ti­dine. Gilead said Wednes­day that the in­creased risk was “pri­mar­i­ly dri­ven by in­fec­tions and res­pi­ra­to­ry fail­ure.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER